IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 325 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $703,080 | +185900.0% | 15,500 | +55.0% | 0.00% | -100.0% |
| Q4 2022 | $378 | -99.9% | 10,000 | -12.3% | 0.00% | 0.0% |
| Q1 2022 | $407,000 | -94.2% | 11,400 | -95.0% | 0.00% | -87.5% |
| Q4 2021 | $7,016,000 | -2.4% | 229,729 | +7.3% | 0.01% | 0.0% |
| Q3 2021 | $7,189,000 | -26.9% | 214,078 | -13.9% | 0.01% | -50.0% |
| Q2 2021 | $9,834,000 | -12.9% | 248,648 | -1.5% | 0.02% | -5.9% |
| Q1 2021 | $11,285,000 | +105.2% | 252,411 | +162.5% | 0.02% | +88.9% |
| Q4 2020 | $5,500,000 | -73.1% | 96,169 | -77.2% | 0.01% | -82.0% |
| Q3 2020 | $20,454,000 | +53.2% | 421,889 | +87.7% | 0.05% | +38.9% |
| Q2 2020 | $13,351,000 | +16.7% | 224,765 | -5.2% | 0.04% | +2.9% |
| Q1 2020 | $11,436,000 | -40.4% | 237,217 | -25.4% | 0.04% | -25.5% |
| Q4 2019 | $19,179,000 | -12.6% | 318,149 | -14.4% | 0.05% | -25.4% |
| Q3 2019 | $21,943,000 | +28.4% | 371,540 | +39.8% | 0.06% | +31.2% |
| Q2 2019 | $17,084,000 | -29.3% | 265,804 | -10.8% | 0.05% | -31.4% |
| Q1 2019 | $24,177,000 | +77.8% | 297,861 | +12.5% | 0.07% | +79.5% |
| Q4 2018 | $13,597,000 | -13.6% | 264,735 | -13.2% | 0.04% | +11.4% |
| Q3 2018 | $15,733,000 | +131.0% | 305,018 | +97.4% | 0.04% | +105.9% |
| Q2 2018 | $6,810,000 | 0.0% | 154,483 | 0.0% | 0.02% | 0.0% |
| Q1 2018 | $6,810,000 | +5.1% | 154,483 | +19.9% | 0.02% | -29.2% |
| Q4 2017 | $6,479,000 | -17.3% | 128,826 | -16.7% | 0.02% | -17.2% |
| Q3 2017 | $7,839,000 | +43.6% | 154,608 | +46.7% | 0.03% | +16.0% |
| Q2 2017 | $5,460,000 | -20.8% | 105,402 | -38.2% | 0.02% | -34.2% |
| Q1 2017 | $6,892,000 | -28.3% | 170,534 | -15.1% | 0.04% | -17.4% |
| Q4 2016 | $9,612,000 | +16.6% | 200,952 | -13.3% | 0.05% | +21.1% |
| Q3 2016 | $8,245,000 | +66.5% | 231,779 | +8.3% | 0.04% | +35.7% |
| Q2 2016 | $4,953,000 | – | 213,962 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |